anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1361879 Benzoyl esters of 1,8,9-anthracenetriols STERLING WINTHROP GROUP Ltd 23 Nov 1972 [26 Nov 1971] 54927/71 Heading C2C [Also in Division A5] Novel substituted-benzoyl esters of a 1,8,9- anthracenetriol are prepared by reaction of an appropriate 1,8,9-anthracenetriol with a benzoic acid or a functional derivative thereof (preferably the acid chloride) in an inert solvent, in the presence of a catalyst (preferably a nitrogenous base) and under an inert atmosphere. The esters have the general Formula (I) in which each R is hydrogen or an X, Y-substituted benzoyl group and at least one R is the said benzoyl group. X is halogen, hydroxy, nitro, alkyl, alkoxy, aryloxy trifluoromethyl or an optionally substituted alkyl- or aryl-carboxy group, Y is hydrogen or X and R 1 is hydrogen or methyl. Compounds prepared are the tribenzoyl esters in which Y is hydrogen X is nitro, hydroxymethyl, acetoxy or chloro and R 1 is hydrogen and also 1,8,9-tri-(2-hydroxy-benzoyloxy)-3-methyl-anthracene and the mono- or di- (2-acetoxy-benzoyl)esters of 1,8,9-anthracenetriol. These anthracene derivatives are useful in treating inflammatory conditions of the skin and form with a suitable vehicle a pharmaceutical composition which may be administered topically. The composition may also contain salicylic acid and/or hydrocortisone.
[GB1361879A]
Patients may receive up to 6 treatments of Melphalan/HDS 3.0 mg/kg IBW. Each treatment cycle consists of 6 weeks with an acceptable delay for an additional 2 weeks (i.e. 8 weeks in total). The maximum dose of melphalan will be 220 mg per treatment.
PROBLEM TO BE SOLVED: To provide a system for preventing a forgery or alternation or a mistake in kind of medicine or dosage in an outside prescription. SOLUTION: Each hospital and each medicine preparing pharmacy are connected to a management center, respectively, through communication lines. The hospital delivers an outside prescription to a patient and transmits the data to the management center through the communication line. The management center accumulates the past prescriptions every patient. The medicine preparing pharmacy transmits the information for the outside prescription brought by the patient from an information terminal to the management center according to an ID every hospital or the like, and checks whether the descried contents of the outside prescription are identical or not, and gives a medicine to the patient on the basis of the prescription when there is no problem.  The pharmacy further confirms the history or the like of the patient and also whether the medication is not excessive, or the combination of medicines is correct. Since the pharmacy can confirm the prescription in the management center controlling a plurality of hospitals and medicine preparing pharmacies, a medication mistake can be prevented even if the patient is attended to a plurality of hospitals.
After a fall leading to hip fracture, patients are cared for by orthopedists and receive internal fixation or arthroplasty. Consultations for internal medicine care are occasionally made depending on the patient's condition. During the first 1 to 2 days after surgery, nurses teach patients how to exercise while still in bed, using caution while changing their position. Pain-relief medications and antibiotics are also administered (for 2-3 days). The first day after surgery, physical therapy usually starts with rehabilitation training only on patients receiving arthroplasty. The average hospital stay is 5 to 7 days. After hospital discharge, very few patients use in-home or community rehabilitation or are admitted to a 2-week subacute rehabilitation unit. Patients usually come back to the clinic around 1, 3, 6, and 12 months after hospital discharge. However, adherence to this follow-up schedule is poor. Telephone follow-ups are seldom used.
A substantially non-ionic colloidal ferric hydroxide-hydrogenated dextran complex is made by blending a purified colloidal ferric hydroxide solution, made by dialysing a colloidal ferric hydroxide solution against distilled water until a pH of above 3.5 is reached, with a hydrogenated dextran having an average intrinsic viscosity of 0.03 to 0.15, measured in water at 25 DEG  C., and being substantially non-reducing to Somogyi reagent.  The weight ratio of hydrogenated dextran to ferric iron in solution may be between 0.5:1 and 2:1, and the complex may be formed by agitation of the blended solutions at 50-90 DEG  C.  The resulting colloidal solution of complex may be of pH 5.0-7.0 and may contain 1 to 25 weight per cent of elementary iron.  The colloidal solution of complex may be concentrated by evaporation of water under reduced pressure, or the solid complex may be precipitated from aqueous solution by addition of a water-miscible organic solvent.  The hydrogenation of dextran with sodium borohydride, and the synthesis of dextran using Leuconostoc mesenteroides is described. Aqueous solutions of the complex are used in treating iron-deficiency anaemia (see Division A5).ALSO:Injectable compositions for use in treating iron-deficiency anaemia comprise a sterile aqueous solution of a non-ionic colloidal ferric hydroxide-hydrogenated dextran complex, made by mixing a ferric hyroxide solution (pH above 3.5) with a non-reducing hydrogenated dextran having an average intrinsic viscosity, in water at 25 c of 0.03-0.15.  The composition may have an intravenous toxicity in mice of LD50 value above 2000 mg/kg.  The compositions may be partially or wholly dehydrated-e.g. by evaporation under reduced pressure, or precipitation with organic solvents and subsequent desiccation-to yield paste or solid materials useful for oral administration, or reconstitution with water to provide an injectable composition.
PROBLEM TO BE SOLVED: To obtain a skin preparation for external use, capable of sufficiently manifesting actions essentially possessed by a pharmacodynamically effective ingredient and stable and excellent antiinflammatory actions and extremely useful for the beauty culture and medicine by combining a lignan glycoside with the pharmacodynamically effective ingredient. SOLUTION: This skin preparation for external use is obtained by formulating a lignan glycoside with an antiinflammatory agent in combination. The lignan glycoside is a sesaminol glycoside represented by the formula [R1 and R2 are each a glycosyl composed of one to four saccharides, which are one or more selected from the group of glucose, galactose and fructose; (a) to (c) are each 0 or 1], especially a compound represented by formula II (Glc is the glycosyl) or formula III or IV is preferred. The amount thereof formulated is 0.001-5 wt.% in the case of using, e.g. the compound represented by formula I to IV. As an antiinflammatory agent, glycyrrhizic acid, glycyrrhetinic acid, mefenamic acid, phenylbutazone, etc., are preferable. The amount thereof formulated is 0.0001-10 wt.%.  The skin preparation for external use has excellent preventing effects on skin aging, reducing effects on skin roughening and humectant effects.
This national single-centre, experimental, randomized and controlled trial will comprise two parallel arms. The intervention to be studied will be an alternative application of riboflavin drops in the inferior fornix. As comparator serves a conventional riboflavin drop application directly on the center of the cornea. Our research hypothesis is that the application of riboflavin drops in the inferior fornix is not inferior to the corneal application with respect to the resulting riboflavin concentrations in the anterior chamber; which represents a sufficient corneal impregnation with riboflavin. This study is randomized but not blinded. Recruitment is anticipated to start in September 2019 and is scheduled to last 1-2 months. We will enroll 12 patients in each trial arm.
TAK-510 at starting dose of 5 microgram (mcg) or placebo-matching solution, subcutaneously, once on Day 1. Staggered dosing will be done in the first cohort of Part A (Cohort 1). Staggered dosing in subsequent Cohorts (Cohorts 2-12 and 21-25) will be used based on emerging safety, tolerability, and PK data from Cohort 1 as determined in the dose escalation meeting.
Sensorineural hearing loss (SNHL) is mainly caused by injury or loss of hair cells (HCs) and associated spiral ganglion neurons (SGNs) in the inner ear. At present, there is still no effective treatment for SNHL in clinic. Recently, advances in organoid bring a promising prospect for research and treatment of SNHL. Meanwhile, three-dimensional (3D) printing provides a tremendous opportunity to construct versatile organoids for tissue engineering and regenerative medicine. In this study, gelatin (Gel), sodium alginate (SA), and polyvinyl alcohol (PVA) were used to fabricate biomimetic scaffold through 3D printing. The organ of Corti derived from neonatal mice inner ear was seeded on the PVA/Gel/SA scaffold to construct organ of Corti organoid. Then, the organ of Corti organoid was used to study the potential protective effects of berberine sulfate on neomycin-juried auditory HCs and SGNs. The results showed that the PVA/Gel/SA biomimetic 3D scaffolds had good cytocompatibilities and mechanical properties. The constructed organoid could maintain organ of Corti activity well in vitro. In addition, the injury intervention results showed that berberine sulfate could significantly inhibit neomycin-induced HC and SGN damage. This study suggests that the fabricated organoid is highly biomimetic to the organ of Corti, which may provide an effective model for drug development, cell and gene therapy for SNHL.
Open limb fractures are severe orthopedic injuries and at an increased risk for complications including nonunion and infection. Rates of infection are dependent upon features such as extent of soft tissue trauma, patient characteristics, degree of contamination and modifiable factors such as time to surgical debridement and IV (intravenous) antibiotics. Surgical debridement within 24 hours and IV antibiotics are the current standard of care, but despite advances in care, the infection rates for these injuries has remained stable over the last several decades.

Possible explanations for this stagnation in care may be related to the current standard of care and the pathophysiology of open fractures. There is significant soft-tissue damage in open fractures, which compromises local vasculature leading to devascularized soft tissue and bone. This devitalized tissue serves as a nidus for infection, a base for biofilm production and reduces the level of systemic antibiotics delivered to the zone of injury. Local antibiotic therapy has the potential to overcome these challenges, by allowing a high concentration of antibiotics to be delivered to the devitalized tissue. Additional benefits of local antibiotics are their powdered form, which is stable, easy to transport, and can be applied immediately in austere situations without the need for IV access. A recent randomized control trial found a 4% decrease risk of infection following powdered vancomycin placement at the time of hardware fixation. However, a recent meta-analysis showed nearly a 12% risk reduction in open fractures treated with local antibiotics when compared to the standard of care. However, this meta-analysis was predominantly made up of small retrospective studies, underlying the need for a randomized control trial evaluating the efficacy of local antibiotics in acute open fracture management.

While causative organisms vary with location, cultures from open fractures are positive 83% of the time. Cultures have shown high rates of colonization of both gram-positive organisms (predominantly Staphylococcus aureus and epidermidis) as well as gram-negative organisms (mostly Pseudomonaonas aeruginosa). Given this prevalence the antibiotics vancomycin and tobramycin are likely good candidates given that they have high efficacy against the common colonizing bacteria, are available in standardize powdered formula, reach high local concentrations, and have a minimal cytotoxic effect to local cells6. Using a combination of vancomycin and tobramycin in the acute care of severe open fractures may substantially decrease risks of infection from both gram-positive and gram-negative pathogens.
Live viral vaccine against contagious ecthyma of sheep comprises the attenuated viral strain 'L-1' (deposition number 8). This is isolated from the infected areas of the skin of a lamb and adapted by repeated passages on a primary culture of sheep foetal skin cells. Esp. 10-20 passages on cells from a 3-3.5 month old foetus are carried out at 36-37 deg.C. The attenuated strain is grown on cells of 3-month old sheep foetal skin at 36 deg.C. pref. using medium N199 contg. 2% bovineserum for maintenance. Particularly the virus contg. material is first harvested when 50-70% of the cells are infected and the second harvest is taken 24-36 hrs. later. This vaccine is highly immunogenic, safe and free from contaminating viruses. The attenuated strain can be grown on readily available substrates and provides immunity (which lasts for at least 9 months) against a wide range of epizootic viral strains.
Chronic Whiplash-Associated Disorders (WAD) is a debilitating, costly condition, and remains a challenge for clinicians, including physicians, rehabilitation specialists and physiotherapists. There is now consistent evidence for central sensitization in people with chronic WAD. In a previous study in chronic WAD patients, our group showed that pain inhibition during exercise is impaired and that a submaximal exercise triggers a severe relapse named post-exertional malaise. On the other hand, imbalance of serotonin (5-HT) and norepinephrine (NE) is likely to be responsible for malfunctioning of pain inhibitory pathways. Indeed, NE is required for activation of descending noradrenergic pathways with established nociceptive inhibitory properties. Serotonin reuptake inhibitor drugs activate serotonergic descending pathways that recruit, in part, opioid peptide-containing interneurons in the dorsal horn. It becomes more and more clear that the lack of pain inhibition accounts in part for various symptoms at rest and following exercise in particular (post-exertional malaise). However, the mechanisms behind the lack of pain inhibition during exercise remain to be revealed. Besides the lack of endogenous pain inhibition during exercise in people with chronic WAD, there appears to be sufficient evidence to support the presence of impaired cognitive function in chronic pain patients in general and preliminary evidence in chronic WAD patients in particular.

The present study aimed at examining whether activation of serotonergic and/or noradrenergic descending pathways improves pain inhibition during exercise in chronic WAD patients. In addition, it is aimed at examining whether activation of serotonergic and/or noradrenergic descending pathways prevents post-exertional malaise following submaximal exercise in these patients. A secondary study aim comprises of examining the effect of an acute submaximal exercise with and without activation of serotonergic or noradrenergic descending pathways on chronic WAD patients' cognitive performance. Furthermore, the isolated effect of activated serotonergic and noradrenergic descending pathways on chronic WAD patients' cognitive performance will be studied.We will modulate endogenous serotonergic and adrenergic pain inhibitory mechanisms by using a selective NE reuptake inhibitor (NRI) and a selective 5-HT reuptake inhibitor (SSRI). Endogenous pain inhibition and cognitive function (sustained and selective attention, and executive function) will be studied at rest and in response to exercise (1) under baseline condition, (2) after the intake of a NRI (Atomoxetine), and (3) after the intake of a SSRI (Citalopram).
Constipation is a common condition in children which affects around 10% of the paediatric population. In 95 % cases it is a functional disorder of the digestive tract, without any organic cause. Recommendations of lifestyle modifications accompanying pharmacological treatment of constipation are very popular among healthcare providers, although there is limited data concerning non-pharmacological treatment methods of this condition. Adequate for age fluid intake is now recommended for patients with constipation. Further research is needed to form stronger recommendations in the future. The purpose of this study is to determine whether educational intervention (recommendation of adequate fluid intake) is effective as an element supporting the treatment of functional constipation in children.
Patients will receive 'usual care' left at the discretion of the treating general practitioner (GP). They are expected to follow the Belgian guidelines, which propose education of the patient about the harmful effects of chronic benzodiazepines and z-drugs ((z-)BZD) use, the alternatives, and the advice to discontinue (z-)BZD use. A stepped approach is recommended. First, a minimal intervention strategy such as a discontinuation letter or a short advice is applied. If unsuccessful, a brief intervention, which may span one or more consults, is recommended. During such an intervention, the GP will - based on the principles of motivational interviewing- assess the patient's readiness for change and match the appropriate intervention. A tapering scheme will be developed which typically consists of a 10-20% reduction in the daily dose of the (z-)BZD every 2-4 weeks.
A total of 90 patients were examined in a prospective randomized study. In 60 patients referred for coronary artery bypass grafting (CABG), LIMA was harvested, one-half (n=30) skeletonized, and one-half (n=30) with a pedicle. Thirty patients operated via sternotomy without LIMA harvesting (other procedures, for instance, valve surgery) were the control group. In patients undergoing LIMA harvest, harvest duration, graft length, and graft free flow were measured at defined arterial pressure. In all patients, the sternal blood flow was examined by active dynamic thermography (DIRT): first preoperatively and on 4th postoperative day. During this, the time of spontaneous rewarming of the skin surface after the application of a cold stimulus was measured in the caudal part of the sternum. The difference between postoperative and preoperative time was calculated and compared between groups.
At the completion of surgery, a Foley catheter was left in place. When the patient was determined to be ambulatory by the recovery room nurse, the bladder was backfilled with 300cc of sterile normal saline. Voiding 200cc or (2/3) of the backfill amount was considered passing.
The effervescent tablet contains an effervescent system composed of carrier crystals of at least one solid, edible, organic acid, at least one component which forms gas by reacting with the acid with salt formation and at least one salt formed from the acid and the gas-forming component. A first layer of a different acid and a second layer of a (preferably acidic) salt of at least one of the two acids are applied to the carrier crystals. Of the total amount of the acid(s) used and of the gas-forming components, 10 to 40, in particular 10 to 20, percent by weight are in the form of the salts, preferably in the form of acidic salts. Carrier crystals are, in particular, citric acid, malic acid, tartartic acid, monosodium citrate and/or ascorbic acid. The first layer may contain gluconic acid delta-lactone and is preferably covered with citric acid, malic acid and/or tartaric acid. This is covered with a layer of a monosalt formed by reaction of part of the total amount of the gas-forming component with at least one of the acids used.
Armodafinil or placebo was provided in 50 mg tablet form and subjects were instructed to take 4 tablets orally once daily in the morning. Subjects randomized to the placebo treatment arm for the double-blind treatment period of the study took four placebo tablets and no armodafinil tablets each morning.
Sarcopenia is a progressive disorder characterized by age-related loss of skeletal muscle mass and function. Although significant progress has been made over the years to identify the molecular determinants of sarcopenia, the precise mechanisms underlying the age-related loss of contractile function remains unclear. Advances in "omics" technologies, including mass spectrometry-based proteomic and metabolomic analyses, offer great opportunities to better understand sarcopenia. Herein, we performed mass spectrometry-based analyses of the vastus lateralis from young, middle-aged, and older rhesus monkeys to identify molecular signatures of sarcopenia. In our proteomic analysis, we identified proteins that change with age, including those involved in adenosine triphosphate and adenosine monophosphate metabolism as well as fatty acid beta oxidation. In our untargeted metabolomic analysis, we identified metabolites that changed with age largely related to energy metabolism including fatty acid beta oxidation. Pathway analysis of age-responsive proteins and metabolites revealed changes in muscle structure and contraction as well as lipid, carbohydrate, and purine metabolism. Together, this study discovers new metabolic signatures and offers new insights into the molecular mechanisms underlying sarcopenia for the evaluation and monitoring of a therapeutic treatment of sarcopenia.
The persistence of drug-sensitive tumors poses a significant challenge in cancer treatment. The concept of bacterial persisters, which are a subpopulation of bacteria that survive lethal antibiotic doses, is frequently used to compare to residual disease in cancer. Here, we explore drug tolerance of cancer cells and bacteria. We highlight the fact that bacteria, in contrast to cancer cells, have been selected for survival at the population level and may therefore possess contingency mechanisms that cancer cells lack. The precise mechanisms of drug-tolerant cancer cells and bacterial persisters are still being investigated. Undoubtedly, by understanding common features as well as differences, we, in the cancer field, can learn from microbiology to find strategies to eradicate persisting cancer cells.
PCT No. PCT/JP96/01459 Sec. 371 Date Dec. 2, 1997 Sec. 102(e) Date Dec. 2, 1997 PCT Filed May 30, 1996 PCT Pub. No. WO96/38428 PCT Pub. Date Dec. 5, 1996The present invention provides novel N-benzyldioxothiazolidylbenzamide derivatives that improve the insulin resistance and have potent hypoglycemic and lipid-lowering effects and processes for preparing the same, and relates to N-benzyldioxothiazolidylbenzamide derivatives characterized by being represented by a general formula (1) wherein R1 and R2 denote identically or differently hydrogen atoms, lower alkyl groups with carbon atoms of 1 to 4, lower alkoxy groups with carbon atoms of 1 to 3, lower haloalkyl groups with carbon atoms of 1 to 3, lower haloalkoxy groups with carbon atoms of 1 to 3, halogen atoms, hydroxyl groups, nitro groups, amino groups which may be substituted with lower alkyl group(s) with carbon atoms of 1 to 3 or hetero rings, or R1 and R2 link to form a methylenedioxy group, R3 denotes a lower alkoxy group with carbon atoms of 1 to 3, hydroxyl group or halogen atom, and dotted line indicates double bond or single bond in combination with solid line, and processes for preparing the same.
Treatment consisting of a personalized plantar orthosis fabricated in 4mm polypropylene, which incorporates a 4mm heel rise and metatarsal dome placed proximal to the 2nd-3rd-4th metatarsal heads. No modifications applied to the patients' medial longitudinal arch.Orthosis fabricated following the inverted orthotic technique.